Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations

European Journal of Clinical Investigation

Volumn 30, Issue 7, 2000, Pages 646-652

  Tektonidou, M G ^b   Petrovas, C A ^b   Ioannidis, J P A ^a,c   Vlachoyiannopoulos, P G ^b   Moutsopoulos, Haralampos M ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Antiphospholipid syndrome; Autoantibodies; Enzyme linked immunosorbent assay; Platelet activating factor; Systemic lupus erythematosus; Thrombosis

Indexed keywords

ANTISERUM; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BOVINE SERUM ALBUMIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHATIDYLCHOLINE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUIPMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; ODDS RATIO; PHOSPHATIDYLCHOLINES; PLATELET ACTIVATING FACTOR; SCLERODERMA, SYSTEMIC; SEROEPIDEMIOLOGIC STUDIES; THROMBOSIS;

EID: 0033946660     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00673.x     Document Type: Article

References (32)

1. 1 Harris EN. Syndrome of the Black Swan. Br J Rheumatol 1986;26:324-6.
2. 2 Hughes GRV. The antiphospholipid syndrome. Lupus 1996;5:345-6.
3. 3 Gilman-Sachs A, Lubinski J, Beer AE, Brend S, Beaman KD. Patterns of antiphospholipid antibody specificities. J Clin Lab Immunol 1991;35:83-8.
4. 4 Alarcon-Segovia D, Cabral AR. Functional and immunochemical heterogeneity of antiphospholipid antibodies: a classification. J Rheumatol 1992;198: 1166-9.
5. 5 Vlachoyiannopoulos PG, Beigbeder G, Dueymes M, Youinou P, Hunt JA, Krilis SA et al. Autoantibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus. Their correlation with anticardiolipin antibodies and β2 glycoprotein I plasma levels. Autoimmunity 1993;16:245-9.
6. 6 Roubey RAS. Autoantibodies to phospholipid-binding proteins: a new view of lupus anticoagulants and other 'antiphospholipid antibodies'. Blood 1994;84:2854-67.
7. 7 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2 glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-906.
8. 8 Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S. An explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
9. 9 Matsuda J, Saitoh N, Gohchi K, Goton M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994;47:56-8.
10. 10 Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor: evidence for 1-0-alkyl-2-sn-glyceril-3-phosphoryl-choline as the active component (a new class of lipid chemical mediators). J Biol Chem 1979;254:9355-8.
11. 11 Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent, histamine release from rabbit platelets: the role of IgE, basophils and a platelet-activating factor. J Exp Med 1972;136:1356-77.
12. 12 Benveniste J, Tence M, Varenne J, Bidault J, Boullet C, Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (PAF): PAF-acether an alkyl ether analog of lysophatidylcholine. C R Acad Sci (D) (Paris) 1979;289D:1037-40.
13. 13 Barquinero J, Selva A, Ordi J, Molins A, Tolosa C, Vilardell M. Anti-PAF antibodies in patients with systemic lupus erythematosus, 'primary' antiphospholipid syndrome, progressive systemic sclerosis and syphilis and its correlation with other antiphospholipid antibodies. Br J Rheumatol 1990;24:106 (Abstract).
14. 14 Barquinero J, Ordi-Ros J, Selva A, Perez-Peman P, Vilardell M, Khamashta M. Antibodies against platelet-activating factor in patients with antiphospholipid antibodies. Lupus 1994;3:55-8.
15. 15 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
16. 16 Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
17. 17 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. 18 Vianna J, Khamashta M, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 111 patients. Am J Med 1994;96:3-9.
19. 19 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic, Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
20. 20 Manoussakis MN, Gharavi AE, Drosos AA, Kitridou RC, Moutsopoulos HM. Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol 1987;44:297-307.
21. 21 Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis S, Moutsopoulos HM. Antibodies to β2-Glycoprotein-I: urea resistance, binding specificity, and asssociation with thrombosis. J Clin Immun 1998;18:380-91.
22. 22 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
23. 23 SPSS, Inc. Advanced SPSS, Version 6.1. Chicago: SPSS Inc;1994.
24. 24 Toschi V, Motta A, Castelli C, Gibelli S, Cimminielb C, Molaro GL et al. Prevalence and clinical significance of antiphospholipid to non-cardiolipin antigens in systemic lupus erythematosus. Haemostasis 1993;23:275-83.
25. 25 McNeil HP, Chesterman CN, Krillis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193-280.
26. 26 Gilburd B, Stein M, Tomer Y, Janne D, Abranski O, Chapman T et al. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic? Autoimmunity 1993;16:23-7.
27. 27 Silver RK, Addler L, Hickman AR, Hageman JR. Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am J Obstet Gynecol 1991;165:1748-52.
28. 28 Braquet P, Bourgain R, Mencia-Huerta JM. Effect of platelet-activating factor on platelets and vascular endothelium. Sem Thromb Haemost 1989;15:184-92.
29. 29 Bussolino F, Aglietta M, Sanavio F, Stacchini A, Lauri D, Cammussi G. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol 1985;135:2748-54.
30. 30 Keltai M, Hosford D, Guinot P, Esann A, Branquet P. PAF. a review of its effects, antagonists and possible clinical implications. Part II. Drugs 1991;42:174-204.
31. 31 Marcus AJ, Safier LB, Ulman HL, Wong KTH, Brolkman J, Weksler BB et al. Effects of acetyl glyceryl ether phosphocholine on human platelet function in vitro. Blood 1981;58:1027-31.
32. 32 Suquet CM, Leid DM. Aggregation of equine platelets by PAF (platelet activating factor). Inflammation 1983;7:197-203.